The Changing Landscape of Therapeutic Strategies for Recurrent Ovarian Cancer

Klaus H Baumann; Uwe Wagner; Andreas du Bois


Future Oncol. 2012;8(9):1135-1147. 

In This Article

Future Perspective

Antiangiogenic therapy is further establishing its role in combination and maintenance therapy; resistance mechanisms to antiangiogenic therapy will be clarified and result in subsequent therapeutic recommendations. Basic and clinical research are expected to elucidate the role of immune cells in ovarian cancer growth and progression, and the potential for therapeutic modulation of immune cells in favor of better control of recurrent ovarian cancer. A vast number of targeted therapeutics are waiting to go through the process of clinical testing. Biomarkers are urgently required to identify the right targets and patients for those agents. However, not only new compounds but also established procedures and drugs (e.g., metabolism modifiers and anti-inflammatory drugs) are still to be optimized and evaluated. Thus, to gain benefit for patients with recurrent ovarian cancer, a network of basic, clinical and interdisciplinary research, trials and therapy is needed requiring federal, nonprofit and industrial support.